Combination Therapy With New Targets in Type 2 Diabetes: A REVIEW OF AVAILABLE AGENTS WITH A FOCUS ON PRE-EXERCISE ADJUSTMENT
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
The current strategy for treating type 2 diabetes mellitus promotes combination therapy to address the 3 major defects in type 2 diabetes mellitus: (1) impaired peripheral glucose uptake (liver, fat, and muscle), (2) excessive hepatic glucose release (with glucagon excess), and (3) insufficient insulin secretion. Providers can prescribe medications that may have advantageous secondary effects in a patient-specific manner. Adjustment for exercise is generally necessary only with insulin and with medications that may allow insulin secretion despite decreasing glucose levels, such as sulfonylurea drugs. Recently, newer oral medications that address beta-cell dysfunction have been designed to avoid hypoglycemia and to "match" nutritional and non-nutritional needs more directly. Incorporating these agents into regimens will likely reduce hypoglycemia and therefore increase the safety and efficacy of exercise as both a treatment and cardiac monitoring strategy for patients with diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Weyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940 · cited 1×
“This relative insulin deficiency is due to cellular resistance to insulin action at the levels of the muscle cell, the adipocyte, the hepatocyte, and the $-cell itself.(5,6) In addition, the newest defect to be described in T2DM is abnormally elevated (or inadequately suppressed) glucagon, which promotes glucose produ…”
BackgroundBailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Buchanan, T. A., Xiang, A. H., Peters, R. K., Kjos, S. L., Marroquin, A., Goico, J., Ochoa, C., Tan, S., Berkowitz, K., Hodis, H. N., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.9.2796 · Cited by 1,339
Management of diabetes and hyperglycemia in hospitals.
Clement, S., Braithwaite, S. S., Magee, M. F., Ahmann, A., Smith, E. P., Schafer, R. G., Hirsch, I. B., & on behalf of the Diabetes in Hospitals Writing Committee (2004) · Diabetes Care · doi:10.2337/diacare.27.2.553 · Cited by 1,266 · cited 1×
“However, there remains a theoretical, albeit unclear, disadvantage in using sulfonylureas in the setting of recent cardiac ischemia due to potential effects on ischemic preconditioning.(44) The glinides are newer insulin secretogogues that include the meglitinide repaglinide and the amino acid derivative nateglinide.”
BackgroundKendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Pharmacologic Therapy for Type 2 Diabetes Mellitus
DeFronzo, R. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-4-199908170-00008 · Cited by 1,173
Cited by
Physical activity/exercise and diabetes: A position statement of the American Diabetes Association
Colberg, S. R., Sigal, R. J., Yardley, J. E., Riddell, M. C., Dunstan, D. W., Dempsey, P. C., Horton, E. S., Castorino, K., & Tate, D. F. (2016) · Diabetes Care · doi:10.2337/dc16-1728 · Cited by 2,991
“Some medications (other than insulin) may increase exercise risk and doses may need to be adjusted (150,151).”
BackgroundPharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347
“Exercise adjustment is generally necessary only with insulin and with medications that can promote endogenous insulin secretion despite decreasing glucose levels, such as the sulfonylurea and glinide classes of agents (80).”
BackgroundSelf-citationExercise and Glycemic Control in Diabetes: Benefits, Challenges, and Adjustments to Pharmacotherapy
Gulve, E. A. (2008) · Physical Therapy · doi:10.2522/ptj.20080114 · Cited by 120
Effects of tai chi exercise on patients with type 2 diabetes
Wang, J. H. (2008) · Medicine and Sport Science · doi:10.1159/000134303 · Cited by 33
Metadata
- Authors
- McDonnell, M. E.
- Venue
- Journal of Cardiopulmonary Rehabilitation and Prevention
- Published
- 2007-07
- Volume
- 27
- Issue
- 4
- Pages
- 193-201
- ISSN
- 1932-7501 (ISSN-L)
- OpenAlex
- W2313458506
- Cited by
- 17
- References
- 21
- FWCI
- 1.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combination Therapy With New Targets in Type 2 Diabetes: A REVIEW OF AVAILABLE AGENTS WITH A FOCUS ON PRE-EXERCISE ADJUSTMENT. https://app.cochat.ai/papers/10.1097/01.hcr.0000281762.29287.a6
- The paper
- McDonnell, M. E. (2007). Combination Therapy With New Targets in Type 2 Diabetes: A REVIEW OF AVAILABLE AGENTS WITH A FOCUS ON PRE-EXERCISE ADJUSTMENT. Journal of Cardiopulmonary Rehabilitation and Prevention. https://doi.org/10.1097/01.hcr.0000281762.29287.a6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.